By writer to www.prnewswire.com
CAMBRIDGE, Mass., Could 27, 2020 /PRNewswire/ — Kantum Pharma Inc. (Kantum), a biopharmaceutical firm centered on creating therapies for the prevention and remedy of damaging irritation triggered by the innate immune system, introduced at the moment the publication of recent analysis demonstrating the therapeutic potential of the Firm’s lead program for stopping and treating acute kidney damage (AKI). The paper, which describes the groundbreaking analysis on the uridine diphosphate (UDP)-glucose/P2Y14 receptor signaling pathway within the kidney led by Kantum’s scientific founder Dr. Sylvie Breton, was revealed within the Journal of Clinical Investigation, a number one peer-reviewed translational medication publication. As well as, the journal Nature Reviews Nephrology has revealed a Analysis Spotlight describing the importance of Dr. Breton’s crew’s findings.
The paper elucidates the early and central position of the P2Y14 receptor in initiating irritation inside the kidney after an insult resembling ischemia or trauma. This preliminary innate immune response creates a self-reinforcing inflammatory cascade, usually resulting in AKI. The P2Y14 receptor is activated by UDG-glucose, a danger-signaling molecule that’s launched from confused or broken tissues, and is then concentrated by the kidney. This analysis exhibits that the activation of P2Y14 receptors initiates the secretion of proinflammatory components inside the kidney and quickly causes the recruitment of neutrophils and monocytes, beginning the inflammatory cycle. Moreover, the paper demonstrates the useful results of administering a P2Y14 antagonist to dam the consequences of UDP-glucose and attenuate kidney irritation, harm and lack of perform.
Importantly, these preclinical findings have been additional bolstered by a hanging correlation noticed in ICU sufferers between their threat for creating AKI and the focus of UDP-glucose discovered of their urine. This analysis offers a powerful scientific rationale for Kantum’s lead program KB-1801, which is being developed initially for the prevention of Cardiac Surgical procedure-Related Acute Kidney Harm.
About Cardiac Surgical procedure-Related Acute Kidney Harm (CSA-AKI)
Within the U.S., roughly 600,000 cardiac surgical procedure procedures are accomplished yearly. An estimated 30% of all cardiac surgical procedure sufferers develop AKI. Sufferers experiencing CSA-AKI have a nine-fold elevated threat of in-hospital mortality and vital elevated post-discharge dangers associated to readmission, development to end-stage renal illness, and future mortality. It’s estimated that CSA-AKI creates an incremental burden on the U.S. healthcare system of larger than $7 billion annually.
About Kantum Pharma
Kantum Pharma is a privately held biopharmaceutical firm centered on creating therapies to stop or scale back irritation initiated via the UDP-glucose/P2Y14 purinergic receptor signaling pathway in organs such because the kidneys, lungs and feminine reproductive tract. The Firm’s preliminary small molecule therapeutic program KB-1801 has been proven preclinically to scale back renal irritation and has the potential to rework the remedy paradigm for AKI and delayed graft perform following renal transplant. The Firm can be pursuing extra applications involving lung irritation, together with cystic fibrosis.
The Firm was based based mostly on the pioneering work of Dr. Sylvie Breton’s laboratory at Massachusetts Basic Hospital/Harvard Medical Faculty. Kantum Pharma’s buyers embrace Broadview Ventures and numerous non-public particular person buyers. (www.kantumpharma.com)
For media and investor inquires:
SOURCE Kantum Pharma
— to www.prnewswire.com